Additionally, the reduced mRNA of the Gal-1-receptor (GALR1) via null mutation or administration of galantine—a GALR1 antagonist—in a mouse model of status epilepticus was found to increase damage within the hippocampus, suggesting a role for the GAL1R as a potential therapeutic target in modulating cell death during epileptic insults within the CNS (Schauwecker, 2010). Here, GALR1 is linked to status epilepticus.